According to FutureWise analysis, the market for AIDS Related Primary CNS Lymphoma is estimated to be US$ 1.2 billion in 2023 and is expected to reach US$ 2.05 billion by 2031 at a CAGR of 6.9% over the forecast period of 2023-2031.
Primary CNS lymphoma (PCNSL) has been identified as an AIDS-defining illness since 1983 and constitutes about 15% of non-Hodgkin lymphomas in individuals with HIV. In most cases, HIV-associated PCNSL is linked to the Epstein-Barr virus (EBV). The most common cause is a breakdown in the immune system's ability to regulate EBV, leading to the expression of cancer-causing proteins, a decrease in cell death, and an increase in lymphocyte proliferation. Typically, one or more contrast-enhancing lesions in the upper part of the brain are a manifestation of PCNSL. Symptoms such as headaches, cognitive impairment, focal neurological deficits, and seizures are often experienced by patients. It's crucial to differentiate PCNSL from other potential causes, such as other cancers or infections, with cerebral toxoplasmosis being a significant consideration. Various factors, including magnetic resonance imaging features, 201thallium single-photon emission computed tomography results, the presence of EBV DNA in cerebrospinal fluid, and toxoplasmosis serology, can aid in determining the likelihood of PCNSL or cerebral toxoplasmosis.
On the histopathological confirmation, a definitive diagnosis of PCNSL can be given. When feasible, the preferred initial treatment involves a combination of antiretroviral therapy and high-dose methotrexate-based chemotherapy. An alternative option is combining antiretroviral therapy with whole-brain radiotherapy. While treating EBV with antiviral medications like ganciclovir or zidovudine might be beneficial, further research is needed to establish its effectiveness.
FutureWise Market Research has published a report that provides an insightful analysis of AIDS Related Primary CNS Lymphoma Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts’ projects that AIDS Related Primary CNS Lymphoma Market will experience a significant growth.
According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.